利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

115 条记录 (耗时 0.041 秒)

    ANTIBODIES TO CCR2
    76.
    发明申请
    ANTIBODIES TO CCR2 有权
    抗体CCR2

    公开(公告)号：US20140342450A1

    公开(公告)日：2014-11-20

    申请号：US14244167

    申请日：2014-04-03

    申请人： Amgen Fremont Inc. ,  Pfizer Inc.

    发明人： Ronald P. Gladue ,  Bradley T. Keller ,  Shinji Ogawa ,  Arvind Rajpal ,  Laurie A. Tylaska ,  Shelley Sims Belouski ,  Larry L. Green ,  Meina L. Liang

    IPC分类号： C07K16/28

    CPC分类号： C07K16/2866 ,  A61K2039/505 ,  C07K2317/53 ,  C07K2317/56 ,  C07K2317/76 ,  C07K2317/92

    摘要： Provided are antibodies including human antibodies and antigen-binding portions thereof that specifically bind to CCR2, preferably human CCR2, and that may inhibit CCR2. The present antibodies may bind to the first and/or second extracellular loops of CCR2. Isolated heavy and light chains derived from the antibodies and nucleic acid molecules encoding the antibodies and chains are provided. Methods of making and using the anti-CCR2 antibodies or antigen-binding portions, and compositions comprising these antibodies or antigen-binding portions, including compositions for diagnosis and treatment, are provided. Also provided are gene therapy methods using nucleic acid molecules encoding the heavy and/or light chains that comprise the human anti-CCR2 antibodies or antigen-binding portions thereof.

    摘要翻译： 提供了包括特异性结合CCR2，优选人CCR2的人抗体和其抗原结合部分的抗体，并且可以抑制CCR2。 本抗体可以结合CCR2的第一和/或第二细胞外环。 提供衍生自抗体的分离的重链和轻链以及编码抗体和链的核酸分子。 提供制备和使用抗CCR2抗体或抗原结合部分的方法，以及包含这些抗体或抗原结合部分的组合物，包括用于诊断和治疗的组合物。 还提供了使用编码包含人抗CCR2抗体或其抗原结合部分的重链和/或轻链的核酸分子的基因治疗方法。

    ANTIBODIES TO INSULIN-LIKE GROWTH FACTOR I RECEPTOR
    77.
    发明申请
    ANTIBODIES TO INSULIN-LIKE GROWTH FACTOR I RECEPTOR 审中-公开
    抗胰岛素样生长因子I受体

    公开(公告)号：US20140120089A1

    公开(公告)日：2014-05-01

    申请号：US14135026

    申请日：2013-12-19

    申请人： Pfizer Inc. ,  Amgen Fremont Inc.

    发明人： Bruce D. Cohen ,  Jean Beebe, Jr. ,  Penelope E. Miller ,  James D. Moyer ,  Jose Ramon Corvalan ,  Michael Gallo

    IPC分类号： C07K16/28

    CPC分类号： C07K16/2863 ,  A01K2217/05 ,  A61K31/138 ,  A61K31/513 ,  A61K31/517 ,  A61K31/704 ,  A61K39/39541 ,  A61K39/39558 ,  A61K48/00 ,  A61K2039/505 ,  C07K14/72 ,  C07K16/30 ,  C07K16/40 ,  C07K2317/14 ,  C07K2317/21 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/73 ,  C07K2317/75 ,  C07K2317/76 ,  C07K2317/92 ,  G01N33/574 ,  G01N33/57492 ,  G01N2333/65 ,  G01N2333/71 ,  A61K2300/00

    摘要： The present invention relates to antibodies and antigen-binding portions thereof that specifically bind to insulin-like growth factor I receptor (IGF-IR), which is preferably human IGF-IR. The invention also relates to human anti-IGF-IR antibodies, including chimeric, bispecific, derivatized, single chain antibodies or portions of fusion proteins. The invention also relates to isolated heavy and light chain immunoglobulin molecules derived from anti-IGF-IR antibodies and nucleic acid molecules encoding such molecules. The present invention also relates to methods of making anti-IGF-IR antibodies, pharmaceutical compositions comprising these antibodies and methods of using the antibodies and compositions thereof for diagnosis and treatment. The invention also provides gene therapy methods using nucleic acid molecules encoding the heavy and/or light immunoglobulin molecules that comprise the human anti-IGF-IR antibodies. The invention also relates to gene therapy methods and transgenic animals comprising nucleic acid molecules of the present invention.

    摘要翻译： 本发明涉及特异性结合胰岛素样生长因子I受体（IGF-1R）的抗体及其抗原结合部分，其优选为人IGF-1R。 本发明还涉及人抗IGF-1R抗体，包括嵌合，双特异性，衍生的单链抗体或融合蛋白的部分。 本发明还涉及衍生自抗IGF-1R抗体和编码这种分子的核酸分子的分离的重链和轻链免疫球蛋白分子。 本发明还涉及制备抗IGF-1R抗体的方法，包含这些抗体的药物组合物和使用抗体及其组合物进行诊断和治疗的方法。 本发明还提供使用编码包含人抗IGF-1R抗体的重和/或轻免疫球蛋白分子的核酸分子的基因治疗方法。 本发明还涉及包含本发明的核酸分子的基因治疗方法和转基因动物。

    REDUCING THE RISK OF HUMAN ANTI-HUMAN ANTIBODIES THROUGH V GENE MANIPULATION
    80.
    发明申请
    REDUCING THE RISK OF HUMAN ANTI-HUMAN ANTIBODIES THROUGH V GENE MANIPULATION 失效
    通过V基因操作降低人类抗体抗体的风险

    公开(公告)号：US20120219976A1

    公开(公告)日：2012-08-30

    申请号：US13466888

    申请日：2012-05-08

    申请人： SIRID-AIMÉE KELLERMANN ,  LARRY L. GREEN ,  WOUTER KORVER

    发明人： SIRID-AIMÉE KELLERMANN ,  LARRY L. GREEN ,  WOUTER KORVER

    IPC分类号： G01N33/566

    CPC分类号： G01N33/6854 ,  C07K16/464 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/56 ,  G01N33/5088

    摘要： The present embodiments relate to methods of identifying and creating human or humanized antibodies that possess a reduced risk of inducing a Human Anti-Human Antibody (HAHA) response when they are applied to a human host. Other methods are directed to predicting the likelihood of a HAHA response occurring. Methods for screening for anti-HAHA compounds are also included. Methods for determining if various conditions for administering an antibody to a subject enhance or suppress a HAHA response are also included.

    摘要翻译： 本实施方案涉及鉴定和产生人或人源化抗体的方法，所述人或人源化抗体在应用于人类宿主时具有诱导人抗人抗体（HAHA）应答的风险降低。 其他方法用于预测发生HAHA反应的可能性。 还包括用于筛选抗HAHA化合物的方法。 还包括用于确定对受试者施用抗体的各种条件是否增强或抑制HAHA应答的方法。